Tobramycin in chronic recurrent urinary tract infections

Area of Science:

• Pharmacology
• Infectious Diseases
• Nephrology

Background:

• Chronic recurring urinary tract infections (UTIs) pose a significant clinical challenge.
• Effective and safe treatment options for recurrent UTIs are continually sought.
• Aminoglycosides like tobramycin are used for severe bacterial infections.

Purpose of the Study:

• To evaluate the efficacy and safety of tobramycin in adult patients with chronic recurring UTIs.
• To compare the effectiveness of two different dosing intervals (8-hour vs. 12-hour) for tobramycin therapy.
• To assess the tolerance and potential toxicity of tobramycin in this patient population.

Main Methods:

• A randomized study involving 32 adult patients with chronic recurring UTIs.
• Patients received tobramycin 1.2 mg/kg daily via intramuscular injection at either 8-hour or 12-hour intervals.
• Efficacy was assessed by bacteriuria disappearance, and safety was monitored through clinical observation, audiometry, and laboratory tests.

Main Results:

• An immediate disappearance of bacteriuria was observed in 78.1% of patients post-therapy.
• The cure rate decreased to 60% at 15 days post-therapy.
• No significant difference in efficacy was noted between the 8-hour and 12-hour dosing schedules. Tobramycin demonstrated excellent tolerance, with no injection site reactions or significant laboratory-detected toxicity, except for one patient with chronic renal failure who experienced elevated blood urea.

Conclusions:

• Tobramycin is effective in achieving initial bacteriuria eradication in chronic recurring UTIs.
• The efficacy wanes over a short period, suggesting limitations for long-term management.
• Tobramycin is generally well-tolerated, but caution is advised in patients with pre-existing renal impairment.